We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
下丘脑 Orexin 对肥胖大鼠能量代谢的影响.
- Authors
郝贺玲; 郭菲菲; 孙向荣; 徐珞; 桑艳芳; 公衍玲
- Abstract
Objective: To investigate the effects of hypothalamic administration of OXR-1 selective antagonist ACT-335827 on the metabolism of high-fat diet induced obese rats. Methods: Obese rat model was established by high fat diet feeding. Blood pressure was indirectly measured by blood volume pressure recording (VPR) from the tail using the CODA 8-channel high throughput non-invasive blood pressure system (EMKA). All plasma lipids were measured using commercial enzyme assay kits and a TOSHIBA-40FR fully automated analyzer. Fasting blood glucose was measured using glucose oxidase kit. Fasting insulin was measured by radioimmunoassay. When obese rats displayed metabolic disorders, ACT-335827 was given for the treatment. The changes in body weight, blood pressure, fat, plasma triglycerides, total cholesterol, high density lipoprotein, low density lipoprotein, non-esterified fatty acid (NEFA), leptin, fasting blood glucose and fasting insulin were measured. Results: Compared with standard chow groups, the body weight of rats in high-fat diet groups were significantly increased after 10 weeks of high fat diet feeding (P<0.05). After ACT-335827 treatment, the body weight, blood pressure, fat content and lipid metabolism of rats in standard chow groups did not change significantly (P>0.05); compared with high-fat diet group and high-fat diet with normal saline treatment group, the body weight of high fat diet feeding rats with ACT-335827 treatment was significantly decreased (P<0.05). Similarly, the abdominal and epididymal fat content were decreased (P<0.05); low-density lipoprotein, triglycerides, total cholesterol and leptin levels were decreased (P<0.05); fasting glucose and fasting insulin were significantly reduced (P<0.05) in high-fat diet feeding rats with ACT-335827 treatment. However, blood pressure, mesenteric fat and scapular brown fat, high-density lipoprotein and NEFA of these rats were not remarkably changed (P<0.05).Conclusions: ACT-335827 could improve the metabolic disorders in high fat induced obese rats, and ACT-335827 may play a role in weight loss in high fat induced obese rats.
- Publication
Progress in Modern Biomedicine, 2016, Vol 16, Issue 29, p5625
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/j.cnki.pmb.2016.29.006